The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > ORGANIZATION
ORGANIZATION
- OTC Drug Federation Requests Ministry to Advance Prescription-to-OTC Switches
July 31, 2014
- Generic Drugs See 45.1% Market Share in FY2013 in New Calculation
July 29, 2014
- JPMA President Hints at Adoption of Unified System to Disclose Fees Paid to Doctors Next Year
July 25, 2014
- Kampo Manufacturers Group Names Tsumura President as New Chairman
July 24, 2014
- Number of Drug Reps Rebounds to 65,752 in FY2013, Buoyed by Major Product Debuts
July 23, 2014
- Medwatcher Elbows Expert Group to Disclose Financial Links with HPV Vaccine Makers
July 22, 2014
- Generic Switch Saved 22.7 Billion Yen in Drug Costs over 5 Years: Kyokai Kenpo
July 17, 2014
- JGA to Use Independent Organizations to Conduct GMP Inspections of Overseas Drug Substance Production Facilities
July 17, 2014
- Cochrane Collaboration Establishes Japanese Branch; Co-Director Calls for “Full Disclosure” of Clinical Research
July 14, 2014
- Medwatcher Wants Structural Problems of Pharma Industry and Researchers Revealed During Diovan Trials
July 3, 2014
- JMA Exec Matsumoto Tipped to Replace Adachi as Chuikyo Rep
July 3, 2014
- “No Need to Step Down” as Chair of Biz Lobby, Govt Panel Member: Takeda CEO
July 2, 2014
- Yokokura Reelected as JMA President, 3 Incumbents Retain Veep Seats
July 2, 2014
- Research-Driven Pharmas Could Diverge into 2 Groups Based on Dependence on Off-Patent Drugs: FPMAJ Chair
July 1, 2014
- Min-Iren Urges Novartis to Return “Unfair Profits”
June 24, 2014
- JMA President Yokokura to Serve Second Term
June 20, 2014
- Japan Diabetes Group Announces Recommendations on Proper Use of SGLT-2 Inhibitors
June 17, 2014
- Daiichi Sankyo Pres. Nakayama Elected as New President of PMAT
June 17, 2014
- New Price Cut Rule Barring Generic Replacement of Long-Listed Products: FPMAJ
June 17, 2014
- US-Japan Business Council Airs Concerns over Annual NHI Price Revision
June 13, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…